{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"386"}]}],"title":"30 MIU/day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"382"}]}],"title":"48 MIU/day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"775"}],"units":"Participants"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Number of participants at cycle 6 with dose data","reportingStatus":"POSTED","timeFrame":"Cycle 6. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.","title":"EP2006 Dose (Cycle 6)","type":"PRIMARY","unitOfMeasure":"participants"}